%0 Journal Article
%T Macrolide resistance of Mycoplasma pneumoniae in several regions of China from 2013 to 2019.
%A Jiang Y
%A Dou H
%A Xu B
%A Xu B
%A Zhou W
%A Wang H
%A Ge L
%A Hu Y
%A Han X
%A Qin X
%A Li J
%A Ye L
%A Wu L
%A Zuo H
%A Zhang Q
%A Liu L
%A Hu W
%A Shao J
%A Yin Q
%A Han L
%A Fu X
%A Dong X
%A Dong Y
%A Fu Y
%A Zhao M
%A Sun Q
%A Huo J
%A Liu D
%A Liu W
%A Li Y
%A Wang Y
%A Xin D
%A Shen K
%J Epidemiol Infect
%V 152
%N 0
%D 2024 Apr 18
%M 38634450
%F 4.434
%R 10.1017/S0950268824000323
%X This paper retrospectively analysed the prevalence of macrolide-resistant Mycoplasma pneumoniae (MRMP) in some parts of China. Between January 2013 and December 2019, we collected 4,145 respiratory samples, including pharyngeal swabs and alveolar lavage fluid. The highest PCR-positive rate of M. pneumoniae was 74.5% in Beijing, the highest resistance rate was 100% in Shanghai, and Gansu was the lowest with 20%. The highest PCR-positive rate of M. pneumoniae was 74.5% in 2013, and the highest MRMP was 97.4% in 2019; the PCR-positive rate of M. pneumoniae for adults in Beijing was 17.9% and the MRMP was 10.48%. Among the children diagnosed with community-acquired pneumonia (CAP), the PCR-positive and macrolide-resistant rates of M. pneumoniae were both higher in the severe ones. A2063G in domain V of 23S rRNA was the major macrolide-resistant mutation, accounting for more than 90%. The MIC values of all MRMP to erythromycin and azithromycin were ≥ 64 μg/ml, and the MICs of tetracycline and levofloxacin were ≤ 0.5 μg/ml and ≤ 1 μg/ml, respectively. The macrolide resistance varied in different regions and years. Among inpatients, the macrolide-resistant rate was higher in severe pneumonia. A2063G was the common mutation, and we found no resistance to tetracycline and levofloxacin.